国立研究開発法人 国立成育医療研究センター National Center for Child Health and Development

代表: 03-3416-0181 / 予約センター(病院): 03-5494-7300
〈月~金曜日(祝祭日を除く)9時〜17時〉

  • アクセス・交通案内
  • 予約センター
  • MENU

研究者・企業の方へ Scholar & Enterprise

研究者・企業の方へ Scholar & Enterprise

論文

斉藤 和幸

主な論文・総説・著書
1 Evaluation of Safety Plofiles of Blood Cancer Drugs Approved in Japan.
Sachie Kubota, Kazuyuki Saito, Shunsuke Ono, Yasuo Kodama Therapeutic Innovation & Regulatory Science, 50, 228-236 (2016)
2 Safety Profile based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan.
 Sachie Kubota, Kazuyuki Saito, Shunsuke Ono, Yasuo Kodama Drugs in RD, 17, 133-143 (2017)
3 Differences in urinary renal failure biomarkers in cancer patients initially treated with cisplatin
Maeda A., Ando H., Ura T., Muro M., Saito K.,Kondo E., Takahashi S.,Ito Y., Mizuno Y., Fujimura A. Anticancer Res 37:5235 ・ 5239 (2017)

石黒 精

主な論文・総説・著書
1 Ishiguro A, Sasaki H, Yahagi N, Kure S, Kato H, Mori R: Needs assessment for collaborative network in pediatric clinical research and education. Pediatr Int 2017; 59: 74-79.
2 Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, Shima M: Pediatric thromboembolism: A national survey in Japan. Int J Hematol 2017; 105: 52-58.
3 Murofushi Y, Furuichi M, Shoji K, Kubota M, Ishiguro A, Uematsu S, Gai R, Miyairi I: Adverse clinical and economic impacts associated with blood culture contamination in a pediatric emergency department. Pediatr Infect Dis J. 2018; 37: 755-758.
4 Nomura O, Mishina H, Jasti H, Sakai H, Ishiguro A: Pediatric residents' perceptions of shift work in ward rotations. Pediatr Int 2017; 59: 1119–1122.
5 Ueda R, Nomura O, Maekawa T, Sakai H, Nakagawa S, Ishiguro A: Independent risk factors for recurrence of apparent life-threatening events in infants. Eur J Pediatr, 2017; 176: 443-448.
6 Utsugisawa T, Uchiyama T, Ogura H, Aoki T, Toki T, Hamaguchi I, Ishiguro A, Ohara A, Kojima S, Ohga S, Ito E, Kanno H: Erythrocyte reduced glutathione is a novel biomarker of Diamond-Blackfan anemia. Blood Cell Mol Dis 2016; 59: 31-36
7 Matsunami M, Ishiguro A, Fukuda A, Sasaki K, Uchida H, Shigeta T, Kanazawa H, Sakamoto S, Ohta, Nakadate H, Horikawa R, Nakazawa A, Ishige M, Mizuta K, Kasahara M: Successful living domino liver transplantation in a child with protein C deficiency. Pediatr Transplant 2015; 19: E70-E74.
8 Nakahata T, Kobayashi T, Ishiguro A, et al, Extensive proliferation of mature connective-tissue type mast cells in vitro. Nature 1986;324:65-67.
9 石黒 精,加藤元博,松本公一(編),はじめて学ぶ小児血液・腫瘍疾患-To do & Not to doで理解する. p130-137,診断と治療社,東京,2017.
10 石黒 精,嶋 緑倫,瀧 正志,他(編),はじめての血友病診療実践マニュアル.東京,診断と治療社,2012.

中村 秀文

主な論文・総説・著書
1 Saito J, Akabane M, Komura M, Nakamura H, Ishikawa Y; Age-Appropriate Pediatric Dosage Forms in Japan Insights into End-User Perceptions From an Observational Cross-Sectional Survey Assessing the Acceptability of Oral Formulation. July 2018 Therapeutic Innovation and Regulatory Science DOI: 10.1177/2168479018791133
2 Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K; Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group.: Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017: 32(11):2071-2078.
3 Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H: Improvement of Pediatric Drug Development:Regulatory and Practical Frameworks. Clinical Therapeutics 2016 Mar;38(3):574-81.
4 Kamei K, Sako M, Ishikawa T, Sato M, Ogura M, Uno T, Kiyotani C, Mori T, Tanaka H, Ito S, Nakamura H.; Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature. Ther Apher Dial. 2015; Oct;19(5):491-6. doi: 10.1111/1744-9987.12302. Epub 2015 Apr 27.
5 Iijima K, Sako M, Nozu K, Nakamura H, et al: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2014;384(9950) October 2014: 1273 - 1281
6 Yoshikawa N, Nakanishi K, Sako M, Nakamura H, et al: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2014 Jul 23. doi: 10.1038/ki.2014.260. [Epub ahead of print]
7 Nakamura H, Ishikawa Y: How do Japanese children take their medicines, and what are pharmacists and paediatricians doing about it? Int. J. of Pharmaceutics. 04/2014; DOI: 10.1016/j.ijpharm.2014.03.053
8 Amstutz U1, Shear NH, Rieder MJ, Nakamura H, et al: Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; Mar 5. doi: 10.1111/epi.12564. [Epub ahead of print]
9 Iijima K, Sako M, Saito Oba M, Nakamura H, et al; Cyclosporine C2 Monitoring for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children:A Multicenter Randomized Phase II Trial. Clinical Journal of the American Society of Nephrology 2014;9(2):1-8
10 Nakamura H, Osawa M, Yokoyama T, et al: Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation. Brain Nerve 2013 ; Sep;65(9):1083-92

中川 聡

主な論文・総説・著書
1 Imai Y, Nakagawa S, Ito Y, Kawano T, Slutsky AS, Miyasaka K. Comparison of lung protection strategies using conventional and high-frequency oscillatory ventilation. J Appl Physiol 91:1836-1844, 2001.
2 Trachsel D, McCrindle, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med 172:206-211, 2005.
3 Kitano Y, Nakagawa S, Kuroda T, et al. Liver position in fetal congenital diaphragmatic hernia retains a prognostic value in the era of lung-protective strategy. J Pediatr Surg 40:1827-32; 2005.
4 Okumura A, Nakagawa S, Kawashima H, et al. Deaths associated with pandemic (H1N1) 2009 among children, Japan, 2009-2010. Emerging Infectious Diseases 2011; 17:1993-2000.
5 Imamura T, Nakagawa S, Goldman RD, Fujiwara T. Validation of pediatric index of mortality 2 (PIM2) in a single pediatric intensive care unit in Japan. Intensive Care Med 2012; 38:649-654.
6 Tokuhira N, Shime N, Inoue M, Kawasaki T, Sakurai Y, Kurosaka N, Ueta I, Nakagawa S. Mechanically ventilated children with 2009 pandemic influenza A/H1N1, Results from the national pediatric intensive care registry in Japan. Pediatr Crit Care Med 2012; 13:E294-98.
7 Takeda S, Kotani T, Nakagawa S, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) severe respiratory failure in Japan. J Anesth 2012; 26:650-57.
8 Shime N, Kawasaki T, Saito O, Akamine Y, Toda Y, Takeuchi M, Sugimura H, Sakurai Y, Iijima M, Ueta I, Shimizu N, Nakagawa S. Incidence and risk factors for mortality in paediatric severe sepsis, results from national paediatric intensive care registry in Japan. Intensive Care Med 2012; 38:1191-97.
9 Nakagawa S, Shime N. Respiratory rate criteria for pediatric systemic inflammatory response syndrome. Pediatr Crit Care Med 2014; 15:182.
10 中川 聡.HFOと肺損傷予防.In 中川 聡編.HFOV(高頻度振動換気法)のすべて.東京.日刊工業新聞社2010;1-20. 中川 聡.小児医療におけるHFO.In 中川 聡編.HFOV(高頻度振動換気法)のすべて.東京.日刊工業新聞社2010;74-93.

小林 徹

主な論文・総説・著書
1 Miura M, Kobayashi T, Kaneko T, Ayusawa M, Fukazawa R, Fukushima N, Fuse S, Hamaoka K, Hirono K, Kato T, Mitani Y, Sato S, MD, Shimoyama S, Shiono J, Suda K, Suzuki H, Maeda J, Waki K, and the Z-score Project 2nd Stage (ZSP2) Study Group, Japanese Society of Kawasaki Disease. Association of severity of coronary artery aneurysms in 1006 patients with Kawasaki disease and risk of later coronary events. JAMA Prdiatr. 2018 Maar 5: e180030. [Epub ahead of print].
2 Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T, Committee of Survey on Infliximab use for Kawasaki disease. Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan. J Pediatr. 2017 Dec 7. pii: S0022-3476(17)31362-8.
3 Fukazawa R, Kobayashi T, Mikami M, Saji T, Hamaoka K, Kato H, Suzuki H, Tsuda E, Ayusawa M, Miura M, Ebata R, Kobayashi T, Yashiro M, Ogawa S. Nationwide Survey of Patients With Giant Coronary Aneurysm Secondary to Kawasaki Disease 1999-2010 in Japan. Circ J. 2017 Aug 30. doi: 10.1253/circj.CJ-17-0433. [Epub ahead of print]
4 Kobayashi T, Matsuyama T, Takeuchi M, Ito S. Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis. Reprod Toxicol. 2016;65:170-178.
5 Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, Arakaki Y, Nakamura T, Nagasawa H, Kato T, Jibiki T, Iwashima S, Yamakawa M, Ohkubo T, Shimoyama S, Aso K, Sato S, Saji T; Z Score Project Investigators. A New Z Score Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method in a Pediatric Population. J Am Soc Echocardiogr. 2016;29:794-801.e29
6 Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Hayashi Y. High PRDM16 expression identifies a poor prognostic subgroup of pediatric acute myeloid leukemia correlated to FLT3-ITD, MLL-Pth, and NUP98-NSD1: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Br J Haematol. 2016;172:581-591.
7 Tanoshima M, Kobayashi T , Tanoshima R, Beyene J, Koren G, Ito S. Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis. Clin Pharmacol Ther. 2015;98:417-441.
8 Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, Ishii Y, Suzuki T, Nakajima K, Sakamoto N, Arakawa H. Efficacy of intravenous immunoglobulin combined with prednisolone for resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163:521-526.
9 Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE Study Group Investigators. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease: a prospective, randomised, open, blinded-endpoint trial. LANCET, 2012;379:1613-1620.
10 Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113:2606-2612.

菊地 佳代子

主な論文・総説・著書
1 Kikuchi K, Miyakawa Y, Ikeda S, Sato Y, Takebayashi T. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults. BMC Health Services Research. 2015, Jan, 22;15:2. doi:10.1186/s12913-015-0681-y
2 Miyakawa Y, Katsutani S, Yano T, Nomura S, Nishiwaki K, Tomiyama Y, Higashihara M, Shirasugi Y, Nishikawa M, Ozaki K, Abe T, Kikuchi K, Kanakura Y, Fujimura K, Ikeda Y, Okamoto S. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015, 102, 654–661.
3 レギュラトリーサイエンス戦略相談のための実務マニュアル‐医薬品‐
一般社団法人ARO協議会 出版 2017
4 アカデミアにおける臨床研究・治験に関する薬事関連Q&A集
一般社団法人ARO協議会 出版 2017
5 吉田 浩輔, 飯泉 祐一, 今村 恭子, 岩崎 幸司, 菊地 佳代子, 北川 雅一, 小林 史明, 小林 慶彦, 浜園 俊郎, 能登原 正一, 松村 雅美. 臨床研究推進ガイドライン. 臨床と薬理. 2012, 40巻, Suppl.2, 128-136.
6 宮川 義隆, 菊地佳代子(監修). いつも薬に恋したい~涙の治験物語~ Pharma Tribune, 2013, Vol.5, No.7‐2014, Vol.6, No.12 (11回連載),
7 菊地佳代子. 臨床研究中核病院としての取り組み 承認に向けた取り組みと私

佐古 まゆみ

主な論文・総説・著書
1 Kubota W, Honda M, Okada H, Hattori M, Iwano M, Akioka Y, Ashida A, Kawasaki Y, Kiyomoto H, Sako M, Terada Y, Hirano D, Fujieda M, Fujimoto S, Masaki T, Ito S, Uemura O, Gotoh Y, Komatsu Y, Nishi S, Maru M, Narita I, Maruyama S: A consensus statement on health-care transition of patients with childhood-onset chronic kidney diseases: providing adequate medical care in adolescence and young adulthood. Clin Exp Nephrol. 2018 ;22:743-751
2 Nagata H, Sato M, Ogura M, Yoshikawa T, Yamamoto K, Matsumura S, Kano Y, Saida K, Sako M, Kamei K, Yoshioka T, Ogata K, Ito S, Ishikura K: Coagulopathy as a complication of kidney biopsies in paediatric systemic lupus erythematosus patients with antiphospholipid syndrome.  Nephrolology. 2018 ;23:592-596
3 Iijima K, Sako M, Kamei K, Nozu K: Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol. 2018 ;33:1499-1455
4 Hama T, Nakanishi K, Sato M, Mukaiyama H, Togawa H, Shima Y, Miyajima M, Nozu K, Nagao S, Takahashi H, Sako M, Iijima K, Yoshikawa N, Suzuki H: Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the cpk mouse, a model of autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2017 ;32:457-465
5 Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K; Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017;32:2071-2078
6 Shima Y, Nakanishi K, Sato M, Hama T, Mukaiyama H, Togawa H, Tanaka R, Nozu K, Sako M, Iijima K, Suzuki H, Yoshikawa N: IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol. 2017 ;32:457-465
7 Hama T, Nakanishi K, Sato M, Mukaiyama H, Togawa H, Shima Y, Miyajima M, Nozu K, Nagao S, Takahashi H, Sako M, Iijima K, Yoshikawa N, Suzuki H: Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the cpk mouse, a model of autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol. 2017 ;32:457-465
8 Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K; Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol. 2017;32:2071-2078
9 Shima Y, Nakanishi K, Sato M, Hama T, Mukaiyama H, Togawa H, Tanaka R, Nozu K, Sako M, Iijima K, Suzuki H, Yoshikawa N: IgA nephropathy with presentation of nephrotic syndrome at onset in children. Pediatr Nephrol. 2017 ;32:457-465
10 Iijima K, Sako M, Nozu K: Rituximab for nephrotic syndrome in children. Clin Exp Nephrol 2017;21:193-202
11 Hattori M, Iwano M, Sako M, , et al : Transition of adolescent and young adult patients with childhood-onset chronic kidney disease from pediatric to adult renal services: a nationwide survey in Japan. Clin Exp Nephrol 2016;20:918-925
12 Kamei K, Ogura M, Sato M, Sako M, et al: Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016 ;31:89-95.

山谷 明正

主な論文・総説・著書
1 Ishida N, Hongo S, Kumano A, Hatta H, Zakoji N, Hirutani M, Yamamoto Y, Aono H, Tuigi M, Suzuki R, Hanamitsu H, Wakasugi E, Takahashi M, Yamatani A:Relationship between Pain and Functional Status in Patients with Amyotrophic Lateral Sclerosis: A Multicenter Cross-Sectional Study. J Palliat Med. 2018;21(5):588-591.
2 渡部 智貴, 加藤 一郎, 山谷 明正, 杉浦 信之:国立病院機構および国立高度専門医療研究センターにおける肝臓病教室についての検討:医療.2017;71(2)79-83.
3 山谷明正:国立病院機構における持参薬鑑別報告マニュアルの作成:社会薬学.2016; 35(1):38-43.
4 Hayashi M, Yamatani A, Funaki H, Miyamoto K:Pharmacoeconomic effect of compliance with pharmacist's intervention based on cancer chemotherapy regimens: a cohort study.J Pharm Health Care Sci. 2015;1:10:1-7.
5 山谷明正:リモートSDV(source data verification)の現状と今後の課題.医療.2015;69(4):190-193.
6 山谷明正:薬剤師による医師業務負担軽減に対する取り組み-金沢医療センターにおけるCDTM事例-.医療.2015;69(3):139-143.
7 井上和紀, 山谷明正:新しいリモートSDV実施方法の提案-汎用性の高いリモートSDVの導入事例-.Clinical Research Professionals.2015;46:5-15.
8 山谷明正:医療機関における原資料マネジメントとリモートSDVの利用について.Jpn Pharmacol Ther.2014;42(7)460-463.
9 Hayashi Makoto, Ohnishi Chie, Sugimura Hayato, Miyazawa Kenji, Yamatani Akimasa, Funaki Hiromu, Miyamoto Kenichi:Incidence of Injection Site Reactions Induced by Vinorelbine and Prevention with Hot Compresses.医薬品情報学;2013:15(1)8-12.
10 山谷明正, 井上和紀, 望月恭子, 森奈海子, 笹浪和秀, 肥田木康彦, 安永昇司, 北川雅一, 榎本有希子, 氏原淳:リモートSDVによる治験効率化の実態と今後への期待.臨床薬理;2013:44(1)47-52.

栗山 猛

主な論文・総説・著書
1 現場発の小児医薬品開発-より有効でより安全な医薬品を子どもたちへ-JAPIC NEWS, 一般財団法人日本医薬情報センター, '2013.10, No.354:'12-13.
2 小児領域におけるネットワーク活動を通した研究者主導臨床試験の支援の現状について, 日本臨床試験学会雑誌, ライフサイエンス出版(株) , 2016.11, Vol.44:90-93.
3 小児医薬品開発の現状と課題、今後の展望安心処方, infobox, IMSジャパン, 2016.11, 第111回:web掲載. 
4 (特集)【小児適応外使用と小児製剤】 小児医薬品開発の現状と課題、今後の展望, 日本病院薬剤師会雑誌, 日本病院薬剤師会, 2017.2, Vol.53:155-157.
5 臨床研究・治験推進next stage-AROとNW機能の連携によるクオリティ向上-, 薬理と治療, ライフサイエンス出版(株) , 2017.8, Vol.45:1232.
6 小児領域における医療情報データベースを活用した安全対策の推進について, ファルマシア, 公益財団法人 日本薬学会, 2018.3, Vol.54 No.3:222-224.
7 小児臨床開発の現状と課題、推進に向けた取組み-未来を担う子どもたちのために-, 薬理と治療, 2018.8, Vol.46:1096.

瀧本 哲也

主な論文・総説・著書
1 Uryu K, Nishimura R, Kataoka K, Sato Y, Nakazawa A, Suzuki H, Yoshida K, Seki M, Hiwatari M, Isobe T, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Koh K, Hanada R, Oka A, Hayashi Y, Ohira M, Kamijo T, Nagase H, Takimoto T, Tajiri T, Nakagawara A, Ogawa S, Takita J:Identification of the Genetic and Clinical Characteristics of Neuroblastomas using Genome-wide Analysis. Oncotarget 18, 107513-107529, 2017.
2 Hishiki T, Watanabe K, Ida K, Hoshino K, Iehara T, Aoki Y, Kazama T, Kihira K, Takama Y, Taguchi T, Fujimura J, Honda S, Matsumoto K, Mori M, Yano M, Yokoi A, Tanaka Y, Fuji H, Miyazaki O, Yoshimura K, Takimoto T, Hiyama E.The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis:Results from the JPLT-2 study. J Pediatr Surg 52, 2051-2055, 2017.
3 Izumi Inoue, Fumiaki Nakamura, Kimikazu Matsumoto, Tetsuya Takimoto, Takahiro Higashi:Cancer in adolescents and young adults: National incidence and characteristics in Japan. Cancer Epidemiol 51, 74-80, 2017.
4 Miyoshi Y, Yorifuji T, Horikawa R, Takahashi I, Nagasaki K, Ishiguro H, Fujiwara I, Ito J, Oba M, Fujisaki H, Kato M, Shimizu C, Kato T, Matsumoto K, Sago H, Takimoto T, Okada H, Suzuki N, Yokoya S, Ogata T, Ozono K.:Childbirth and fertility preservation in childhood and adolescent cancer patients: a second national survey of Japanese pediatric endocrinologists. Clin Pediatr Endocrinol. 26, 81-88, 2017.
5 Osamu Natsume, Shigenori Kabashima, Junko Nakazato, Kiwako Amamoto-Hanada, Masami Narita, Mai Kondo, Mayako Saito, Ai Kishino, Tetsuya Takimoto, Eisuke Inoue, Julian Tang, Hiroshi Kido, Gary W.K. Wong, Kenji Matsumoto, Hirohisa Saito, and Yukihiro Ohya, for the PETIT Study Team : Two-step Egg Introduction for preventing egg allergy in High-risk Infantswith 5 eczema (PETIT study):a double-blind, placebo-controlled, parallel-group randomised clinical trial. Lancet 389, 276-286, 2017.
6 Takaharu Oue, Tsugumichi Koshinaga, Tetsuya Takimoto, Hajime Okita, Yukichi Tanaka, Miwako Nozaki, Masayuki Haruta, Yasuhiko Kaneko and Masahiro Fukuzawa, Renal tumor Committee of the Japanese Children’s Cancer Group (JCCG):Anaplastic histology Wilms’ tumors registered to the Japan Wilms’ Tumor Study Group are less aggressive than that in the National Wilms’ Tumor Study 5. Pediatr Surg Int 32, 851-855, 2016.
7 Yoko Miyoshi, Tohru Yorifuji, Reiko Horikawa, Ikuko Takahashi, Keisuke Nagasaki, Hiroyuki Ishiguro, Ikuma Fujiwara, Junko Ito, Mari Oba, Hiroshi Kawamoto, Hiroyuki Fujisaki, Masashi Kato, Chikako Shimizu, Tomoyasu Kato, Kimikazu Matsumoto, Naohiko Sago, Tetsuya Takimoto, Hiroshi Okada, Nao Suzuki, Susumu Yokoya, Tsutomu Ogata, and Keiichi Ozono : Gonadal function, fertility, and reproductive medicine in childhood and adolescent cancer patients: a national survey of Japanese pediatric endocrinologists. Clin Pediatr Endocrinol 25, 45-57, 2016.
8 Sunami S, Sekimizu M, Takimoto T, Mori T, Mitsui T, Fukano R, Saito AM, Watanabe T, Ohshima K, Fujimoto J, Nakazawa A, Kobayashi R, Horibe K, Tsurusawa M :Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study. Pediatr Blood Cancer 63, 451-457, 2016.
9 瀧本哲也 :小児固形腫瘍の疫学. 小児外科 48,1125-1128,2016.
10 瀧本哲也 :国立成育医療研究センターの固形腫瘍データセンター. 水谷修紀(監修)よくわかる臨床研究 –小児がん-, 132-136, 医薬ジャーナル社, 東京, 2016.

掛江 直子

主な論文・総説・著書
1 掛江直子: 第9章 胎児・小児をめぐる諸問題. 改訂版 生命倫理・医事法,医療科学社, 2018: 147-164.
2 掛江直子: 新・皮膚科セミナリウム 変貌する難病診療の最前線2.小児慢性特定疾病対策のこれから. 日本皮膚科学会雑誌 第128巻第1号,日本皮膚科学会,2018: 41-49.
3 掛江直子: 小児医療における意思決定. 日本医事法学会編「年報医事法学32」, 日本評論社, 2017: 49-56.
4 掛江直子: 染色体・遺伝子検査-1. 総論「染色体, 遺伝子検査の倫理」. 小児臨床検査のポイント2017 小児内科2017vol.49増刊号, 東京医学社, 2017: 666-672.
5 Kenji Takehara , Yoshiyuki Tachibana, Keiko Yoshida, Rintaro Mori, Naoko Kakee, Takahiko Kubo. Prevalence trends of pre-and postnatal depression in Japanese women: A population-based longitudinal study. Journal of Affective Disorders. 2018; 225: 389-394.
6 Hatoko Sasaki, Naoko Kakee, Naho Morisaki, Rintaro Mori, Ulrike Ravens-Sieberer, Monika Bullinger: Assessing health-related quality of life in young Japanese childrenwith chronic conditions: Preliminary validation of the DISABKIDS smiley measure. BMC Pediatrics. 2017: doi:10.1186/s12887-017-0854-4. Published online.
7 Kenji Takehara, Maiko Suto, Naoko Kakee, Yoshiyuki Tachibana, Rintaro Mori. Prenatal and early postnatal depression and child maltreatment among Japanese fathers. Child Abuse & Neglect. 2017; 70: https://doi.org/10.1016/j.chiabu.2017.06.011
8 掛江直子: 新しい小児慢性特定疾病対策について ①新制度の概要とおもな変更点, 小児慢性特定疾病 診断の手引き, 診断と治療社, 2016: 2-5.
9 小児慢性特定疾病情報室(掛江直子 他)編集:小児慢性特定疾病 診断の手引き, 診断と治療社, 2016.
10 掛江直子: よりよい小児がん臨床研究のために求められる研究のあり方「小児がん臨床研究における研究倫理のあり方と特徴」. よくわかる臨床研究~小児がん~, 医薬ジャーナル社, 2016: 160-169
11 掛江直子: Ⅰ.総論「2.小児慢性特定疾病対策と難病対策-法改正ならびに新法成立でどのように変わったか-」, 小児科臨床, 日本小児医事出版社, 69(4), 2016: 505-514

永田 知映

主な論文・総説・著書
1 Nagata C, Moriichi A, Morisaki N, Gai-Tobe R, Ishiguro A, Mori R: Inter-prefecture disparity in under-5 mortality: 115 year trend in Japan. Pediatrics international : official journal of the Japan Pediatric Society 2017, 59(7):816-820.
2 Motomura K, Ganchimeg T, Nagata C, Ota E, Vogel JP, Betran AP, Torloni MR, Jayaratne K, Jwa SC, Mittal S et al: Incidence and outcomes of uterine rupture among women with prior caesarean section: WHO Multicountry Survey on Maternal and Newborn Health. Scientific reports 2017, 7:44093.
3 Morisaki N, Nagata C, Jwa SC, Sago H, Saito S, Oken E, Fujiwara T: Pre-pregnancy BMI-specific optimal gestational weight gain for women in Japan. Journal of epidemiology 2017, 27(10):492-498.
4 Kobayashi S, Hanada N, Matsuzaki M, Takehara K, Ota E, Sasaki H, Nagata C, Mori R: Assessment and support during early labour for improving birth outcomes. The Cochrane database of systematic reviews 2017, 4:Cd011516.
5 Kawabata A, Yanaihara N, Nagata C, Saito M, Noguchi D, Takenaka M, Iida Y, Takano H, Yamada K, Iwamoto M et al: Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. Gynecol Oncol 2017, 146(3):609-614.
6 Chibueze EC, Parsons AJQ, Lopes KDS, Yo T, Swa T, Nagata C, Horita N, Morisaki N, Balogun OO, Dagvadorj A et al: Diagnostic Accuracy of Ultrasound Scanning for Prenatal Microcephaly in the context of Zika Virus Infection: A Systematic Review and Meta-analysis. Scientific reports 2017, 7(1):2310.
7 Ganchimeg T, Nagata C, Vogel JP, Morisaki N, Pileggi-Castro C, Ortiz-Panozo E, Jayaratne K, Mittal S, Ota E, Souza JP et al: Optimal Timing of Delivery among Low-Risk Women with Prior Caesarean Section: A Secondary Analysis of the WHO Multicountry Survey on Maternal and Newborn Health. PloS one 2016, 11(2):e0149091.
8 Rumbold A, Ota E, Nagata C, Shahrook S, Crowther CA: Vitamin C supplementation in pregnancy. The Cochrane database of systematic reviews 2015, 9:Cd004072.
9 Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, Okamoto A: Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy. The journal of obstetrics and gynaecology research 2015, 41(9):1440-1448.
10 Nagata C, Yanagida S, Okamoto A, Morikawa A, Sugimoto K, Okamoto S, Ochiai K, Tanaka T: Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. The journal of obstetrics and gynaecology research 2012, 38(4):639-644.